- Home
- IBRX vs SBLK Comparison
IBRX vs SBLK Comparison
Compare IBRX & SBLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- SBLK
- Stock Information
- Founded
- IBRX 2014
- SBLK 2006
- Country
- IBRX United States
- SBLK Greece
- Employees
- IBRX N/A
- SBLK N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- SBLK Marine Transportation
- Sector
- IBRX Health Care
- SBLK Consumer Discretionary
- Exchange
- IBRX Nasdaq
- SBLK Nasdaq
- Market Cap
- IBRX 2.3B
- SBLK 2.1B
- IPO Year
- IBRX N/A
- SBLK N/A
- Fundamental
- Price
- IBRX $2.76
- SBLK $19.79
- Analyst Decision
- IBRX Strong Buy
- SBLK Strong Buy
- Analyst Count
- IBRX 6
- SBLK 3
- Target Price
- IBRX $9.83
- SBLK $23.00
- AVG Volume (30 Days)
- IBRX 9.7M
- SBLK 1.2M
- Earning Date
- IBRX 11-11-2025
- SBLK 08-06-2025
- Dividend Yield
- IBRX N/A
- SBLK 1.01%
- EPS Growth
- IBRX N/A
- SBLK N/A
- EPS
- IBRX N/A
- SBLK 1.05
- Revenue
- IBRX $56,600,000.00
- SBLK $1,131,251,000.00
- Revenue This Year
- IBRX $629.94
- SBLK N/A
- Revenue Next Year
- IBRX $109.91
- SBLK $18.30
- P/E Ratio
- IBRX N/A
- SBLK $18.34
- Revenue Growth
- IBRX 4227.22
- SBLK 2.95
- 52 Week Low
- IBRX $1.83
- SBLK $12.06
- 52 Week High
- IBRX $7.48
- SBLK $23.82
- Technical
- Relative Strength Index (RSI)
- IBRX 64.62
- SBLK 62.58
- Support Level
- IBRX $2.32
- SBLK $19.06
- Resistance Level
- IBRX $2.67
- SBLK $19.57
- Average True Range (ATR)
- IBRX 0.14
- SBLK 0.44
- MACD
- IBRX 0.05
- SBLK 0.02
- Stochastic Oscillator
- IBRX 72.73
- SBLK 99.32
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.